Stockreport

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traum...

Alzamend Neuro, Inc.  (ALZN) 
PDF Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the studyHead-to-head study of AL001 versus a marketed lithiu [Read more]